CELZ (Creative Medical Technology Holdings) Moat Score: 2/10 (As of Jul. 03, 2026)


CELZ Creative Medical Technology Holdings Inc CELZ
36 GF Score
Price $1.21
GF Value $0.32
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings Moat Score?

Creative Medical Technology Holdings CELZ -3.20% 36 Moat Score is 2 as of Jul. 03, 2026. GuruFocus rates CELZ with a GF Score™ of 36/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,399 Biotechnology companies, Creative Medical Technology Holdings ranks better than 58.11% on this metric.

Creative Medical Technology Holdings has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Creative Medical Technology Holdings has No Moat: Creative Medical Technology Holdings has minimal market presence and lacks significant intellectual property or cost advantages. The company's competitive position is weak, with no clear customer loyalty or pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Creative Medical Technology Holdings might have No Moat - Very weak/transient advantages.

Creative Medical Technology Holdings  (NAS:CELZ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Creative Medical Technology Holdings Moat Score Related Terms

CELZ vs FBLG, GLMD, ALZN: Moat Score Comparison

For the Biotechnology subindustry, Creative Medical Technology Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Creative Medical Technology Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Creative Medical Technology Holdings's Moat Score falls into.


CELZ
36GF Score
Creative Medical Technology Holdings Inc CELZ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Creative Medical Technology Holdings (CELZ) has a Moat Score of 2 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Creative Medical Technology Holdings ranks #586 out of 1399 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Creative Medical Technology Holdings' Moat Score too high?
Creative Medical Technology Holdings' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Creative Medical Technology Holdings' value of 2 is 0% at this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #586 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Creative Medical Technology Holdings has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Moat Score compare to FBLG and GLMD?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #586 out of 1399 companies for Moat Score. This puts Creative Medical Technology Holdings in the upper half of its industry. The industry median Moat Score is 2.00. Creative Medical Technology Holdings' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $1.21 — trading 278.1% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Creative Medical Technology Holdings' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Moat Score is 2 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $1.21 is trading 278.1% above its estimated GF Value™ of $0.32. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • Moat Score: 2
  • GF Value™: $0.32 vs. price of $1.21 (278.1% above fair value)
  • GF Score™: 36/100 with 4 warning signs
  • Industry Position: 0% at the Biotechnology median (#586 of 1399)

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
36GF Score

Get the complete analysis for CELZ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.21
Price
$0.32
GF Value